NASDAQ (usa) | 6715.56 | -12.11 | -0.18% | |
FTSE 100 (london) | 7487.96 | -5.12 | -0.07% | |
DAX (german) | 13465.51 | 235.94 | 1.78% | |
NIKKEI 225 (japan) | 22420.08 | 408.47 | 1.86% | |
Hang - Seng (hong kong) | 28594.06 | 348.52 | 1.23% |
NIFTY - 50 (india) | ||||
Straits Times (singapore) | 3391.61 | 17.53 | 0.52% | |
KOSPI (korea) | 2556.47 | 33.04 | 1.31% | |
All Ordinaries (australia) | 6005.30 | 28.90 | 0.48% | |
BOVESPA (brazil) | 74092.76 | -215.73 | -0.29% |
ISHITA DRUGS & INDUSTRIES LTD. (BSE: 524400)
524400 Technical Analysis
1.5
As on 18th Apr 2024 524400 SHARE Price closed @ 70.90 and we RECOMMEND Buy for LONG-TERM with Stoploss of 70.55 & Sell for SHORT-TERM with Stoploss of 72.13 we also expect STOCK to react on Following IMPORTANT LEVELS. |
524400SHARE Price
Open | 70.94 | Change | Price | % |
High | 70.95 | 1 Day | -0.02 | -0.03 |
Low | 67.80 | 1 Week | -0.49 | -0.69 |
Close | 70.90 | 1 Month | 6.45 | 10.01 |
Volume | 2044 | 1 Year | 22.90 | 47.71 |
52 Week High 98.37 | 52 Week Low 46.01 |
BSE INDIA Most Active Stocks
532822 | 13.20 | 2.17% |
532775 | 1.77 | 3.51% |
512149 | 1.05 | 3.96% |
532648 | 23.89 | -0.29% |
517001 | 0.09 | 12.50% |
504351 | 2.27 | 4.61% |
532407 | 132.51 | 19.99% |
532532 | 21.34 | 1.81% |
511389 | 7.25 | -2.42% |
534690 | 7.65 | 4.79% |
BSE INDIA Top Gainers Stocks
BSE INDIA Top Losers Stocks
524400 Daily Charts |
524400 Intraday Charts |
Whats New @ Bazaartrend |
524400 Free Analysis |
|
524400 Important Levels Intraday
RESISTANCE | 76.97 |
RESISTANCE | 75.02 |
RESISTANCE | 73.82 |
RESISTANCE | 72.62 |
SUPPORT | 69.18 |
SUPPORT | 67.98 |
SUPPORT | 66.78 |
SUPPORT | 64.83 |
524400 Target April 2024
4th UP Target | 92.31 |
3rd UP Target | 83.74 |
2nd UP Target | 78.44 |
1st UP Target | 73.14 |
1st DOWN Target | 58.02 |
2nd DOWN Target | 52.72 |
3rd DOWN Target | 47.42 |
4th DOWN Target | 38.85 |
524400 Weekly Target
4th UP Target | 80.71 |
3rd UP Target | 77.76 |
2nd UP Target | 75.93 |
1st UP Target | 74.11 |
1st DOWN Target | 68.89 |
2nd DOWN Target | 67.07 |
3rd DOWN Target | 65.24 |
4th DOWN Target | 62.29 |
524400 Target2024
4th UP Target | 164.05 |
3rd UP Target | 134.51 |
2nd UP Target | 116.25 |
1st UP Target | 97.99 |
1st DOWN Target | 45.89 |
2nd DOWN Target | 27.63 |
3rd DOWN Target | 9.37 |
4th DOWN Target | -20.17 |
ISHITA DRUGS & INDUSTRIES LTD. ( BSE INDIA Symbol : 524400 )
Sector : Other And Other Stocks in Same Sector
Sector : Other And Other Stocks in Same Sector
524400 Other Details
Segment | EQ | |
Market Capital | 64291448.00 | |
Sector | Other | |
Industry | Other | |
Offical website | > echo $website ; ?> |
524400 Address
524400 Latest News
524400 Business Profile
Ishita Drugs & Industries Limited manufactures and sells active pharma ingredients and drug intermediates in India. It offers active pharma ingredients, such as sulfa drugs/sulfonamides, vitamins, fluoro quinolones, antibiotics, anthelmintics, iodides and citrates, food additives/excipients, and others; fine chemicals; and drug intermediaries, as well as finished dosage forms. The company also provides contract manufacturing services for various drug intermediates, fine chemicals, or specialty chemicals. It serves regulatory authorities and pharmaceutical companies. The company exports its products to approximately 25 countries. Ishita Drugs & Industries Limited was incorporated in 1992 and is based in Ahmedabad, India. Address: 401, 3rd Eye II, Ahmedabad, India, 380006
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service